Advertisement

Treatment Approaches for Dry AMD

  • Z. Yehoshua
  • P. J. RosenfeldEmail author
Chapter

Abstract

The overall goal of treating dry AMD is to target the underlying cause of the disease and prevent, or at least slow, the loss of vision, which requires the preservation of the choroid, RPE, and photoreceptors.

Keywords

Glatiramer Acetate Geographic Atrophy Complement Inhibition Fluocinolone Acetonide Choroidal Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthal­mology 99(6):933–943PubMedGoogle Scholar
  2. 2.
    Friedman DS, O’Colmain BJ, Munoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122(4):564–572PubMedCrossRefGoogle Scholar
  3. 3.
    Ferris FL, Davis MD, Clemons TE et al (2005) A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol 123(11):1570–1574PubMedCrossRefGoogle Scholar
  4. 4.
    Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119(10):1417–1436CrossRefGoogle Scholar
  5. 5.
    Evans J (2008) Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye (Lond) 22(6):751–760CrossRefGoogle Scholar
  6. 6.
    Thornton J, Edwards R, Mitchell P et al (2005) Smoking and age-related macular degeneration: a review of association. Eye (Lond) 19(9):935–944CrossRefGoogle Scholar
  7. 7.
    Seddon JM, Cote J, Rosner B (2003) Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 121(12):1728–1737PubMedCrossRefGoogle Scholar
  8. 8.
    Ding X, Patel M, Chan CC (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28(1):1–18PubMedCrossRefGoogle Scholar
  9. 9.
    Kaidzu S, Tanito M, Ohira A et al (2008) Immunohistochemical analysis of aldehyde-modified proteins in drusen in cynomolgus monkeys (Macaca fascicularis). Exp Eye Res 86(5):856–859PubMedCrossRefGoogle Scholar
  10. 10.
    Parodi MB, Virgili G, Evans JR (2009) Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev 2009 Jul 8;(3):CD006537Google Scholar
  11. 11.
    Csaky KG, Richman EA, Ferris FL 3rd (2008) Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium. Invest Ophthalmol Vis Sci 49(2):479–489PubMedCrossRefGoogle Scholar
  12. 12.
    Ralston PG Jr, Sloan D, Waters-Honcu D et al (2010) A Pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci 51:E-Abstract 913Google Scholar
  13. 13.
    Tao W, Wen R, Goddard MB et al (2002) Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43(10):3292–3298PubMedGoogle Scholar
  14. 14.
    Beltran WA, Zhang Q, Kijas JW et al (2003) Cloning, mapping, and retinal expression of the canine ciliary neurotrophic factor receptor alpha (CNTFRalpha). Invest Ophthalmol Vis Sci 44(8):3642–3649PubMedCrossRefGoogle Scholar
  15. 15.
    Emerich DF, Thanos CG (2008) NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 10(5):506–515PubMedGoogle Scholar
  16. 16.
    Williams GA, Tao W (2009) A phase II study of encapsulated CNTF secreting cell implant (NT-501) in patients with visual acuity impairment associated with atrophic macular degeneration. Invest Ophthalmol Vis Sci 50:E-Abstract 5003Google Scholar
  17. 17.
    Mata NL, Vogel R (2010) Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 21(3):190–196PubMedCrossRefGoogle Scholar
  18. 18.
    Saylor M, McLoon LK, Harrison AR et al (2009) Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 127(4):402–406PubMedCrossRefGoogle Scholar
  19. 19.
    Schmitz-Valckenberg S, Holz FG, Bird AC et al (2008) Fundus autofluorescence imaging: review and perspectives. Retina 28(3):385–409PubMedCrossRefGoogle Scholar
  20. 20.
    Radu RA, Han Y, Bui TV et al (2005) Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 46(12):4393–4401PubMedCrossRefGoogle Scholar
  21. 21.
    Kubota R, Birch D, David R (2009) Phase 1, dose-escalating study of the safety, tolerability, and pharmacokinetics of ACU-4429 in healthy volunteers. Invest Ophthalmol Vis Sci 50:E-Abstract 5009Google Scholar
  22. 22.
    Johnson LV, Leitner WP, Rivest AJ et al (2002) The Alzheimer’s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99(18):11830–11835PubMedCrossRefGoogle Scholar
  23. 23.
    Ding JD, Lin J, Mace BE et al (2008) Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 48(3):339–345PubMedCrossRefGoogle Scholar
  24. 24.
    Beatty S, Koh H, Phil M et al (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45(2):115–134PubMedCrossRefGoogle Scholar
  25. 25.
    Group Age-Related Eye Disease Study Research (2000) Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study report number 3. Ophthalmology 107(12):2224–2232CrossRefGoogle Scholar
  26. 26.
    Tanito M, Li F, Elliott MH et al (2007) Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci 48(4):1900–1905PubMedCrossRefGoogle Scholar
  27. 27.
    Sternberg P, Rosenfeld PJ, Slakter JS et al (2010) Topical OT-551 for treating geographic atrophy: Phase II results. Invest Ophthalmol Vis Sci 51:E-Abstract 6416Google Scholar
  28. 28.
    Wong WT, Kam W, Cunningham D et al (2010) Topical administration of anti-oxidant, OT-551 for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 51:E-Abstract 6418Google Scholar
  29. 29.
    Gehrs KM, Jackson JR, Brown EN et al (2010) Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 128(3):349–358PubMedCrossRefGoogle Scholar
  30. 30.
    Anderson DH, Radeke MJ, Gallo NB et al (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95–112PubMedCrossRefGoogle Scholar
  31. 31.
    Skeie JM, Fingert J, Russell S et al (2010) Complement component C5a activates Icam-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2010 Oct;51(10):5336-42PubMedCrossRefGoogle Scholar
  32. 32.
    Patel M, Chan CC (2008) Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 30(2):97–110PubMedCrossRefGoogle Scholar
  33. 33.
    Klein ML, Ferris FL 3rd, Francis PJ et al (2010) Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010 Aug;117(8):1554–9, 1559.e1PubMedCrossRefGoogle Scholar
  34. 34.
    Scholl HP, Fleckenstein M, Fritsche LG et al (2009) CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 4(10):e7418PubMedCrossRefGoogle Scholar
  35. 35.
    Nozaki M, Raisler BJ, Sakurai E et al (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 103(7):2328–2333PubMedCrossRefGoogle Scholar
  36. 36.
    Holers VM et al (2009) TT30, a novel human protein therapeutic, selectively modulates the complement alternative pathway by targeted supplementation of local factor H activity. In: 51st Annual Meeting of the American Society of Hematology New OrleansGoogle Scholar
  37. 37.
    Risitano AM et al (2009) TT30, a novel regulator of the complement alternative pathway (CAP), inhibits hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes and prevents upstream C3 binding on their surface in an in vitro model. In: 51st Annual Meeting of the American Society of Hematology New OrleansGoogle Scholar
  38. 38.
    Landa G, Butovsky O, Shoshani J et al (2008) Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 33(11):1011–1013PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Bascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations